Literature DB >> 22167324

Erythropoietin produced by the retina: its role in physiology and diabetic retinopathy.

Cristina Hernández1, Rafael Simó.   

Abstract

Erythropoietin (Epo) is the principal regulator of erythropoiesis by inhibiting apoptosis and by stimulating the proliferation and differentiation of erythroid precursor cells. However, Epo also performs extra-erythropoietic actions of which the neuroprotective effects are among the most relevant. Apart from kidney and liver, Epo is also produced by the brain and the retina. In addition, Epo receptor (Epo-R) expression has also been found in the brain and in the retina, thus suggesting an autocrine/paracrine action which seems essential for the physiological homeostasis of both brain and retina. In this review, we will give an overview of the current concepts of the physiology of Epo and will focus on its role in the retina in both normal conditions and in the setting of diabetic retinopathy. Finally, the reasons as to why Epo could be contemplated as a potential new treatment for the early stages of diabetic retinopathy will be given.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22167324     DOI: 10.1007/s12020-011-9579-6

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  77 in total

1.  [Effects of glucose on growth, metabolism and EPO expression in recombinant CHO cell cultures].

Authors:  X M Sun; Y X Zhang
Journal:  Sheng Wu Gong Cheng Xue Bao       Date:  2001-11

Review 2.  Erythropoietin after a century of research: younger than ever.

Authors:  Wolfgang Jelkmann
Journal:  Eur J Haematol       Date:  2007-01-23       Impact factor: 2.997

Review 3.  Effects of erythropoietin on brain function.

Authors:  W Jelkmann
Journal:  Curr Pharm Biotechnol       Date:  2005-02       Impact factor: 2.837

4.  Landmark advances in the development of erythropoietin.

Authors:  James W Fisher
Journal:  Exp Biol Med (Maywood)       Date:  2010-12

5.  Purification of human erythropoietin.

Authors:  T Miyake; C K Kung; E Goldwasser
Journal:  J Biol Chem       Date:  1977-08-10       Impact factor: 5.157

6.  Alpha2 adrenergic modulation of NMDA receptor function as a major mechanism of RGC protection in experimental glaucoma and retinal excitotoxicity.

Authors:  Cun-Jian Dong; Yuanxing Guo; Peter Agey; Larry Wheeler; William A Hare
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-06-19       Impact factor: 4.799

7.  Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor.

Authors:  Michael Brines; Giovanni Grasso; Fabio Fiordaliso; Alessandra Sfacteria; Pietro Ghezzi; Maddalena Fratelli; Roberto Latini; Qiao-Wen Xie; John Smart; Chiao-Ju Su-Rick; Eileen Pobre; Deborah Diaz; Daniel Gomez; Carla Hand; Thomas Coleman; Anthony Cerami
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-29       Impact factor: 11.205

8.  Erythropoietin protects the in vitro blood-brain barrier against VEGF-induced permeability.

Authors:  Ofelia María Martínez-Estrada; Elisabeth Rodríguez-Millán; Esther González-De Vicente; Manuel Reina; Senén Vilaró; Myriam Fabre
Journal:  Eur J Neurosci       Date:  2003-11       Impact factor: 3.386

Review 9.  Cytokine receptor signalling.

Authors:  J N Ihle
Journal:  Nature       Date:  1995-10-19       Impact factor: 49.962

10.  Tyrosine 343 in the erythropoietin receptor positively regulates erythropoietin-induced cell proliferation and Stat5 activation.

Authors:  J E Damen; H Wakao; A Miyajima; J Krosl; R K Humphries; R L Cutler; G Krystal
Journal:  EMBO J       Date:  1995-11-15       Impact factor: 11.598

View more
  14 in total

1.  Epo inhibits the fibrosis and migration of Müller glial cells induced by TGF-β and high glucose.

Authors:  Wentao Luo; Liumei Hu; Weiye Li; Guotong Xu; Linxinyu Xu; Conghui Zhang; Fang Wang
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-02-23       Impact factor: 3.117

Review 2.  Novel targets against retinal angiogenesis in diabetic retinopathy.

Authors:  Shuang Wang; James K Park; Elia J Duh
Journal:  Curr Diab Rep       Date:  2012-08       Impact factor: 4.810

3.  Diabetic Retinopathy-Update on Prevention Techniques, Present Therapies, and New Leads.

Authors:  Lauren M Marozas; Patrice E Fort
Journal:  US Ophthalmic Rev       Date:  2014

4.  Aqueous levels of erythropoietin in acute retinal vein occlusion with macular edema.

Authors:  Hyun Jin Shin; Hyung Chan Kim; Jun Woong Moon
Journal:  Int J Ophthalmol       Date:  2014-06-18       Impact factor: 1.779

Review 5.  Neuropeptides and diabetic retinopathy.

Authors:  Robert Gábriel
Journal:  Br J Clin Pharmacol       Date:  2013-05       Impact factor: 4.335

Review 6.  Revisiting the role of erythropoietin for treatment of ocular disorders.

Authors:  S L Shirley Ding; S N Leow; R Munisvaradass; E H Koh; M L C Bastion; K Y Then; S Kumar; P L Mok
Journal:  Eye (Lond)       Date:  2016-06-10       Impact factor: 3.775

7.  Genetics in diabetic retinopathy: current concepts and new insights.

Authors:  Olga Simó-Servat; Cristina Hernández; Rafael Simó
Journal:  Curr Genomics       Date:  2013-08       Impact factor: 2.236

8.  Erythropoietin reduces storage lesions and decreases apoptosis indices in blood bank red blood cells.

Authors:  Oscar Andrés Penuela; Fernando Palomino; Lina Andrea Gómez
Journal:  Rev Bras Hematol Hemoter       Date:  2015-11-27

9.  Involvement of Renin-Angiotensin System in Retinopathy of Prematurity - A Possible Target for Therapeutic Intervention.

Authors:  Madhu Nath; Parijat Chandra; Nabanita Halder; Baskar Singh; Ashok Kumar Deorari; Atul Kumar; Rajvardhan Azad; Thirumurthy Velpandian
Journal:  PLoS One       Date:  2016-12-29       Impact factor: 3.240

10.  Systemic treatment with erythropoietin protects the neurovascular unit in a rat model of retinal neurodegeneration.

Authors:  Stephanie Busch; Aimo Kannt; Matthias Kolibabka; Andreas Schlotterer; Qian Wang; Jihong Lin; Yuxi Feng; Sigrid Hoffmann; Norbert Gretz; Hans-Peter Hammes
Journal:  PLoS One       Date:  2014-07-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.